These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11936566)

  • 1. Pharmacokinetic study of infusional valspodar.
    Ma MK; McLeod HL; Westervelt P; Fracasso PM
    J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM; Westervelt P; Fears CL; Rosen DM; Zuhowski EG; Cazenave LA; Litchman M; Egorin MJ
    J Clin Oncol; 2000 Mar; 18(5):1124-34. PubMed ID: 10694566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
    ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
    Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
    Advani R; Fisher GA; Lum BL; Hausdorff J; Halsey J; Litchman M; Sikic BI
    Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration.
    Kovarik JM; Purba HS; Pongowski M; Gerbeau C; Humbert H; Mueller EA
    Pharmacotherapy; 1998; 18(6):1230-6. PubMed ID: 9855321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.
    Binkhathlan Z; Hamdy DA; Brocks DR; Lavasanifar A
    Xenobiotica; 2010 Jan; 40(1):55-61. PubMed ID: 19903013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
    Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL
    Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
    Fracasso PM; Blum KA; Ma MK; Tan BR; Wright LP; Goodner SA; Fears CL; Hou W; Arquette MA; Picus J; Denes A; Mortimer JE; Ratner L; Ivy SP; McLeod HL
    Br J Cancer; 2005 Jul; 93(1):46-53. PubMed ID: 15942626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.
    Carlson RW; O'Neill AM; Goldstein LJ; Sikic BI; Abramson N; Stewart JA; Davidson NE; Wood WC;
    Cancer Invest; 2006 Nov; 24(7):677-81. PubMed ID: 17118777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
    Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
    Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
    Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
    Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD
    J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    Lhommé C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MM; Gordon AN; Fracasso PM; Mietlowski WL; Jones GJ; Dugan MH
    J Clin Oncol; 2008 Jun; 26(16):2674-82. PubMed ID: 18509179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.
    Ortega I; Rodriguez M; Suarez E; Perez-Ruixo JJ; Calvo R
    Pharm Res; 2007 Jul; 24(7):1299-308. PubMed ID: 17380267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
    Krishna R; McIntosh N; Riggs KW; Mayer LD
    Clin Cancer Res; 1999 Oct; 5(10):2939-47. PubMed ID: 10537363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
    Kovarik JM; Mueller EA; Richard F; Tetzloff W
    J Clin Pharmacol; 1997 Nov; 37(11):1009-14. PubMed ID: 9505993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cyclosporin: influence of rate-duration profile of an intravenous infusion in renal transplant patients.
    Gupta SK; Bakran A; Johnson RW; Rowland M
    Br J Clin Pharmacol; 1989 Mar; 27(3):353-7. PubMed ID: 2655684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.